Ani Pharmaceuticals (ANIP) Long-Term Deferred Tax (2014 - 2026)

Ani Pharmaceuticals has disclosed Long-Term Deferred Tax across 13 years of filings, most recently posting $71.5 million for Q2 2026.

• In Q2 2026, Long-Term Deferred Tax fell 22.31% year-over-year to $71.5 million; the TTM figure through Jun 2026 stood at $71.5 million (down 22.31% YoY), while the FY2025 annual figure was $69.1 million, down 18.84% from the prior year.
• Long-Term Deferred Tax came in at $71.5 million for Q2 2026 at Ani Pharmaceuticals, up from $66.6 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $92.0 million in Q2 2025 to a low of $66.6 million in Q1 2026.
• Average Long-Term Deferred Tax over 5 years is $79.7 million, with a median of $81.2 million recorded in 2022.
• Year-over-year, Long-Term Deferred Tax surged 41.4% in 2022 and decreased 24.79% in 2026.
• Over 5 years, Long-Term Deferred Tax stood at $81.4 million in 2022, then climbed by 11.49% to $90.7 million in 2023, then dropped by 6.18% to $85.1 million in 2024, then slipped by 18.84% to $69.1 million in 2025, then advanced by 3.51% to $71.5 million in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $71.5 million in Q2 2026, $66.6 million in Q1 2026, and $69.1 million in Q4 2025.